Personalised medical plan and nutritional monitoring

Lifestyle changes, diet, and physical activity are key components in the treatment of obesity. Only when these measures are not sufficient is it necessary to consider treating obesity with medications, endoscopic procedures, or surgery. 

The pharmacological treatment of obesity has advanced significantly in recent years, with the introduction of medications that achieve greater weight loss than previous generations and that are always used as part of an individualized treatment plan.

GLP-1 receptor agonists and dual GLP-1 and GIP receptor agonists can produce significant, dose-dependent weight loss that is maintained for as long as treatment continues. Their effects are not limited to weight loss. They act on the central mechanisms that regulate appetite and satiety, improve metabolic parameters such as blood glucose levels and lipid profiles, and have demonstrated benefits in comorbidities such as metabolic liver disease and obstructive sleep apnea, as well as reducing cardiovascular risk. Research in this field remains highly active, with new molecules currently under development.

The indication for treatment, the choice of medication, and dose adjustments must always be determined under the guidance of a physician who has a comprehensive understanding of the patient’s health and takes into account other medical conditions, current medications, and potential adverse effects.

Obesity is a chronic disease, so pharmacological treatment should be considered a lifelong chronic therapy. When treatment is discontinued, it is common to regain some of the weight lost. This should be taken into account from the outset when planning the treatment approach with the medical team.